1、Biopharma|Healthtech|Dx/Tools|DeviceEngage#SVBHealthcareFinancialPublished on January 6,202303Market Highlights25Healthcare Fundraising and Investments26Computational Biology Investments29Healthcare M&A and IPO Activity38Healthcare Outlook:2023 and Beyond40GlossaryHEALTHCARE INVESTMENTS AND EXITS|AN

2、NUAL REPORT 20222Note:1)Market statistics represent SVB commercial bank clients as of 12/31/2022 with a VC-backed round of at least$4M.2)The LIPO(Likely to IPO)list tracks Top 15 Crossover-funded private mezzanine deals($40M+)as a proxy for IPO sentiment and pipeline.All investment data as of 12/16/

3、2022.Source:PitchBook and SVB proprietary data.SVB US Market Stats1 2021-2022of all VC-backed US healthcare companies that raised rounds since 2021 have a banking relationship with SVB.of all VC-backed US healthcare companies that raised rounds greater than$40M since 2021 have a banking relationship

4、 with SVB.72%54%3HEALTHCARE INVESTMENTS AND EXITS|ANNUAL REPORT 2022Venture capital(VC)fundraising was unprecedented in H1 2022.Despite a slowdown in H2,funds closed out the year with nearly$22B to invest into healthcare companies,second only to the record$28B raised in 2021.With over$50B fundraised

5、 in the past two years,venture healthcare has the largest war chest of investable capital ever.Healthcare Investment declined in both deals and dollars each quarter after setting a record in 2021.Total healthcare investment for the year still exceeded 2020,making 2022 the second-largest year ever,th

6、ough Q3 and Q4 fell below 2020s quarterly average.This decrease was likely because investors directed new money toward their existing portfolios instead of new investments,raising insider rounds to focus on hitting valuation inflections before the next outside financing.Additionally,the large crosso